Open Nav

Zynerba Pharmaceuticals

  • Armando Anido, Zynerba Pharmaceuticals

Investor outreach, potential ex-US partnerships

  • Date:Wednesday, October 17
  • Time:3:00 PM - 3:15 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Cannabinoids appear to modulate a number of systems, channels and receptors; as such, they may have the potential to be developed in a number of additional important indications, including anxiety, autism spectrum disorder, neuroprotection, cognitive disorders, sleep disturbance, and treatment for certain neuralgias. The Company's lead product candidate, ZYN002, is currently being developed in Fragile X syndrome (pivotal study) and refractory epilepsies (Phase 2), including adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE), a heterogeneous group of rare and ultra-rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances.
  • Company Website:
  • Company HQ City:Devon, PA
  • Company HQ Country:United States
  • Company HQ State:Pennsylvania           
  • Market Cap:120M
  • Ticker:ZYNE
  • Exchange:NASDAQ
  • CEO/Top Company Official:Armando Anido
  • Year Founded:2015
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :ZYN002
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
Armando Anido
Zynerba Pharmaceuticals